Have a feature idea you'd love to see implemented?
Let us know!
TFFP TFF Pharmaceuticals Inc
Price (delayed)
$0.3402
Market cap
$1.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.03
Enterprise value
-$1.04M
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms
Highlights
The debt has plunged by 61% YoY and by 29% from the previous quarter
The EPS has soared by 54% year-on-year and by 20% since the previous quarter
TFF Pharmaceuticals's gross profit has increased by 25% YoY but it has decreased by 3.4% from the previous quarter
The revenue is up by 25% year-on-year but it is down by 3.4% since the previous quarter
TFF Pharmaceuticals's quick ratio has shrunk by 92% YoY and by 45% QoQ
The equity has dropped by 77% year-on-year and by 47% since the previous quarter
Key stats
What are the main financial stats of TFFP
Market
Valuations
Earnings
Shares outstanding
4.44M
Market cap
$1.51M
Enterprise value
-$1.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.9
Revenue
$1.16M
EBIT
-$18.52M
EBITDA
-$17.97M
Free cash flow
-$12.64M
Per share
Balance sheet
Liquidity
EPS
-$6.03
Free cash flow per share
-$2.89
Book value per share
$0.91
Revenue per share
$0.27
TBVPS
$1.62
Total assets
$7.08M
Total liabilities
$3.94M
Debt
$52,403
Equity
$3.14M
Working capital
-$432,348
Debt to equity
0.02
Current ratio
0.89
Quick ratio
0.66
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
-1,547.5%
Gross margin
100%
Net margin
-1,595%
Operating margin
-1,610.8%
Return on assets
-196.1%
Return on equity
-310.2%
Return on invested capital
-863.3%
Return on capital employed
-590.4%
Return on sales
-1,595%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TFFP stock price
How has the TFF Pharmaceuticals stock price performed over time
Intraday
-2.91%
1 week
-9.55%
1 month
-85.21%
1 year
-95.43%
YTD
-95.15%
QTD
-83.07%
Financial performance
How have TFF Pharmaceuticals's revenue and profit performed over time
Revenue
$1.16M
Gross profit
$1.16M
Operating income
-$18.7M
Net income
-$18.52M
Gross margin
100%
Net margin
-1,595%
The net margin has grown by 38% YoY
The operating margin has grown by 37% YoY
TFF Pharmaceuticals's gross profit has increased by 25% YoY but it has decreased by 3.4% from the previous quarter
The revenue is up by 25% year-on-year but it is down by 3.4% since the previous quarter
Growth
What is TFF Pharmaceuticals's growth rate over time
Valuation
What is TFF Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.38
P/S
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.9
The EPS has soared by 54% year-on-year and by 20% since the previous quarter
TFFP's price to book (P/B) is 90% lower than its 5-year quarterly average of 3.9 and 80% lower than its last 4 quarters average of 1.9
The equity has dropped by 77% year-on-year and by 47% since the previous quarter
The stock's price to sales (P/S) is 89% less than its last 4 quarters average of 11.5
The revenue is up by 25% year-on-year but it is down by 3.4% since the previous quarter
Efficiency
How efficient is TFF Pharmaceuticals business performance
The return on equity has dropped by 113% year-on-year and by 38% since the previous quarter
The ROIC has dropped by 82% year-on-year and by 35% since the previous quarter
TFF Pharmaceuticals's return on assets has decreased by 45% YoY and by 15% QoQ
The ROS is up by 38% year-on-year
Dividends
What is TFFP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TFFP.
Financial health
How did TFF Pharmaceuticals financials performed over time
The total assets is 80% more than the total liabilities
TFF Pharmaceuticals's quick ratio has shrunk by 92% YoY and by 45% QoQ
The current ratio has plunged by 91% YoY and by 45% from the previous quarter
The debt is 98% less than the equity
TFFP's debt to equity has surged by 100% since the previous quarter and by 100% year-on-year
The equity has dropped by 77% year-on-year and by 47% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.